Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margo De Velder

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Advanced Drug Delivery Reviews|June 25, 2026
Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapiesIlia Goemaere, Margo De Velder, Stefaan C De Smedt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 24, 2026
Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell EngineeringLaure Harinck, Stijn De Munter, Margo De Velder, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 2, 2024
Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteriaSofie Meulewaeter, Ilke Aernout, Joke Deprez, et al.
Molecular Therapy. Methods & Clinical Development|June 16, 2025
Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigsSofie Meulewaeter, Margo De Velder, Diethard Reckelbus, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Advanced Drug Delivery Reviews|June 25, 2026
Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapiesIlia Goemaere, Margo De Velder, Stefaan C De Smedt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 24, 2026
Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell EngineeringLaure Harinck, Stijn De Munter, Margo De Velder, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 2, 2024
Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteriaSofie Meulewaeter, Ilke Aernout, Joke Deprez, et al.
Molecular Therapy. Methods & Clinical Development|June 16, 2025
Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigsSofie Meulewaeter, Margo De Velder, Diethard Reckelbus, et al.
Pageof 1